- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02799134
Neural Mechanism of Cortisol Awakening Response Suppression Effect on Human High-order and Social Cognitions (NMCARSEHHSC)
April 21, 2022 updated by: qinshaozheng
CAR is short for cortisol awakening response.
The neural mechanism of CAR effect on high-order cognition and social cognition is less known...
Study Overview
Study Type
Interventional
Enrollment (Actual)
67
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100875
- Beijing Normal University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 26 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy college students.
Exclusion Criteria:
- Current or history of psychiatric or neurological illness.
- Current use of any medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: group1
take Dexamethasone at 22:00 on the first day, 0.5mg
|
|
|
Placebo Comparator: group2
take Vitamin C at 22:00 on the first day, 0.5mg
|
|
|
Other: group3
take Dexamethasone at 15:00 on the second day, 0.5mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cortisol Awakening Response Level(nmol/L) after Taking Dexamethasone
Time Frame: one year
|
The dosage of Dexamethasone is 0.5mg.
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Shaozheng Qin, Doctor, Beijing Normal University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
April 10, 2017
Study Completion (Actual)
April 30, 2017
Study Registration Dates
First Submitted
April 6, 2016
First Submitted That Met QC Criteria
June 9, 2016
First Posted (Estimate)
June 14, 2016
Study Record Updates
Last Update Posted (Actual)
April 22, 2022
Last Update Submitted That Met QC Criteria
April 21, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Dexamethasone
- Ascorbic Acid
Other Study ID Numbers
- ICBIR_A_0098_002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.